Ocrevus (ocrelizumab) es un anticuerpo monoclonal humanizado diseñado para atacar selectivamente las células B positivas para CD20, un tipo específico de célula inmunitaria que se cree que contribuye de manera clave al daño de la mielina y de las células nerviosas axonales. Ocrevus está indicado como tratamiento tanto para las recaídas (RMS) y primaria progresiva (PPMS) forms of multiple sclerosis.
Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis.
Zejula (niraparib) is an oral, poly ADP-ribose polymerase (PARP) inhibitor for the maintenance treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.
Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC).
Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinsons disease (PD) experiencing off episodes.
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor indicated for the combination treatment of postmenopausal women with HR+/HER2- metastatic breast cancer.
Noctiva (desmopressin acetate) is vasopressin analog nasal spray indicated for the treatment of nocturia due to nocturnal polyuria.
Odactra (house dust mite allergen extract) is a sublingual allergy immunotherapy (SLIT) tablet indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis.
Xermelo (telotristat ethyl) is an oral tryptophan hydroxylase inhibitor indicated for use in combination with somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors.
Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes.
Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.
Emflaza (deflazacort) is a glucocorticoid for the treatment of Duchenne Muscular Dystrophy.
Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
AirDuo RespiClick (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma.
ArmonAir RespiClick (fluticasone propionate) is an inhaled corticosteroid in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma.
Trulance (plecanatide) is a guanylate cyclase-C agonist for the treatment of chronic idiopathic constipation in adults.
Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults.
Vantrela ER (hydrocodone bitartrate) is an abuse deterrent opioid formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
Arymo ER (morphine sulfate) is an extended-release, abuse-deterrent, opioid analgesic formulation for the management of severe pain.

1. New Drugs to Eliminate MalariaResearchers from the Burnet Institute, Monash University, and Deakin University in Australia were able to cut down the supply of proteins to the Malaria parasite essential for its survival. Since the Malaria parasite lives inside the RBC, the immune system is not able to detect it. Tania de Koning-Ward, co-author of the paper and an eminent member of Deakins Medical School, published her findings in Nature. She said that the research had shown that the proteins could get access to the RBC through a single entrance, which eventually provided a path to get into the RBC so that it could survive and multiply. The scientists managed to change the function of this entry point so that the proteins could not get into the RBC, and then starve and kill the parasite.

The research targets the single gateway for drug treatments considering the fact that it is used by the parasite to obtain the proteins.

2. Breakthrough in the Treatment of Cancer

Gleevec, which is also known as Imatinib, is greatly considered a miracle drug to many. It was initially given an approval in 2001 by the US Food and Drug Administration to cure Chronic Myelogenous Leukemia (CML). The drug has had a phenomenal success rate, with Complete Hematologic Responses (CHR) being observed in 53 fuera de 54 pacientes, according to oncologist, Biran Duker. Each patient was given a regular dosage of 300 mg and the response was evident within the first four weeks following therapy.

Recientemente, the results of a follow-up study which lasted for five years were outstanding. en este estudio, researchers found that after five years of therapy with Gleevec, 98% of patients exhibited a CHR. Además, the overall survival rate after five years was 89% and the relapse rate was a mere 17%. All of these findings have proved the impressive nature of Gleevec.

Antibodies Attacking A Cancer Cell

3. New Strategy for the Discovery of Drugs

Scientists at The Scripps Research Institute (TSRI) have devised a new strategy for the discovery of drugs that allows researchers to choose the chemical compounds that can impact cells in a technique required for the treatment of a particular disease. In order to emphasize the power of this technique, the team at TSRI used this strategy to determine a compound that has the potential to treat diabetes linked to obesity. They were also successful in identifying the fat-cell enzyme that is inhibited by the compound. Interestingly enough, this enzyme has not yet been thought to treat diabetes.

Enrique Saez, Associate Proffesor or TSRI and senior author of the study, said that the strategy developed has the power to speed up the discovery of vital biological pathways, which may result in the accelerated development of new drugs for various diseases.

4. New Drug Discovery Technique to Target a Class of Enzymes

A research headed by the University of Dundee has enhanced the power of developing new drugs that focus on a class of enzymes involved in major diseases like neurodegenerative condition and even cancer. The research team has been targeting the class of enzymes known as deubiquitylases (DUBs). The human genome has been found to have close to 90 DUBs, which are active in every process.

In future, drugs targeting elements of the ubiquitin system will be of crucial importance to the pharmaceutical sector. Dr. Matthias Trost, the leader of the team, said that this is the first technique which permits the high-throughput screening of DUBs, which is of great significance in identifying new targets for the administration of drugs as well as the development of medication.

5. Serelaxin from Novartis-a Breakthrough Therapy in the Treatment of Heart Failure

Swiss pharmaceutical firm, Novarits, recently stated that the US Food and Drug Administration had given the breakthrough therapy status to Serelaxin, which is used in the treatment of acute heart failure. According to Novartis, the FDAs decision was based by safety and efficacy outcomes from a late stage trial of its drug, Serelaxin. The study also proved that the drug cut down the deaths of patients by 37% at six months following acute heart failure in comparison to patients receiving standard therapy.

Last year. Novartis had said that Serelaxin was a promising drug to be released soon, while analysts at Deutsche bank had predicted that the drug could pull in $2.5 billion annual through its sales.

6. Vertex Pharmaceuticals New Drug Combination can Treat Cystic Fibrosis

The task of getting a medication right from conception to the market is the toughest job of all. Added to this, it can consume anywhere between $1-$5 billion dollars and a decade of effort. Even then, the chances of failure seem to be high at every step. Considering the massive amount of failure rate and uncertainty, the news of Vertex Pharmaceuticals new drug combination which can treat Cystic Fibrosis comes as a huge respite. This is a huge triumph for researchers who have been since ages trying to find a cure for this disease.

Cystic Fibrosis, which affects close to 30,000 individuals in the US alone and more than 75,000 across the globe, was not treatable until now. Vertex Pharmaceuticals decided to target an important protein in Cystic Fibrosis, referred to as the Cystic Fibrosis Transmembrane Conductance Regulator or CFTR, whose key role is to transport chloride ions to the lungs and away from them.

7. Promising Treatment for Multiple Sclerosis

Multiple Sclerosis is an autoimmune disease that can cause serious harm to the spinal cord and brain. The symptoms include restricted movement and profound fatigue. It usually affects people between the ages of 20 a 50. The disease harms a fatty membrane, referred to as myelin, which safeguards nerve fibers in the central nervous system. Tim Coetzee, Doctor, chief research officer of the National Multiple Sclerosis Society says that new research has opened up opportunities for treatment at an early stage with therapies that modify the disease.

Researchers and neurologists are presently working on the best MS medications available. Jeffrey K. Huang, Doctor, a lead researcher of the drug at the MS Society Cambridge Centre for Myelin Repair, University of Cambridge, England says that a new treatment allows the Myelin Sheath Invigorate with the help of synthetic chemicals that activate Retinoid Acid Receptor (RXR) within the brainstem cells of an adult. RXR assists the transformation of adult stem cells into oligodendrocytes-cells that produce myelin.

8. Discovery of Ebola Protein could Lead to Drug Development

Recientemente, Africa has been plagued by the deadly Ebola virus. There has been very little scientific research breakthrough with researchers trying to unravel the mystery behind this disease. Sin embargo, scientists at the Icahn School of Medicine at Mount Sinai, the University of Texas Southwestern Medical Center and Washington University in St. Louis may be able to crack the code on how this virus destroys the immune system and find out ways to prevent the disease.

The team sheds light on a unique mechanism of the Ebola virus that obstructs the efforts by interferons-protective proteins- to stop the virus from infecting the cells of the body. Dr. Christopher Basler at the Ichan School of Medicine states that these details can be the foundation to the development of the drug that can combat the Ebola virus.

9. New Ebola Drug Cures Monkeys in Clinical Trial

The cure for the fatal Ebola virus may finally have just been discovered. Recientemente, there has been reports by scientists of Ebola-infected monkeys being completely cured. The medication, Zmapp, is at present being used to treat patients infected with the virus including William Pooley-a British nurse-who is currently being treated at London-based Royal Free hospital after contracting the disease in Sierra Leone.

Around 18 monkeys infected with Ebola were found to be totally cured after being administered ZMapp. Los resultados, according to experts, were heavily encouraging. Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine, stated that these trials now have a strong backing and should be used in humans. On the other hand, it should be noted that two patients treated with the drug had died, but it may have been because the drug was administered too late for it to be effective.

10. New Drug could Treat Most Aggressive Form of Lung Cancer

Scientists have found a new drug that could possibly treat small cell lung cancer, the most destructive form of the disease. Actualmente, this drug is undergoing clinical trials and could potentially be used to treat patients who have tumours that are not affected by chemotherapy treatment. The findings were published in the Clinical Cancer Research and could help in finding out those patients who have greater chances to respond to the treatment. The medication works by analyzing energy production in cancer cells as a means to prohibit tumour growth.

Professor Caroline Dive, the leader of the research, said that small cell lung cancer has a dim prognosis and there has not been any significant breakthrough in its treatment. The drug named AZD3965 has not yet been experimented with in small cell lung cancer.

The quality of life has undoubtedly become rich with these major scientific breakthroughs, sin embargo; still further research and testing needs to be done before these findings can ever be implemented for the well-being of society.

terapia con células madre